Indeed, data from a clinical trial show that in patients with heart failure the treatment with Infliximab, a chimeric monoclonal antibody to TNF-α, or Etanercept, a soluble TNF receptor, increased mortality [72]. This evidence concerns the gene TNF and heart failure.